Strs Ohio trimmed its position in shares of Syneos Health Inc (NASDAQ:SYNH) by 3.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,900 shares of the company’s stock after selling 1,100 shares during the quarter. Strs Ohio’s holdings in Syneos Health were worth $1,489,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. BB&T Corp boosted its position in shares of Syneos Health by 26.7% in the 3rd quarter. BB&T Corp now owns 6,602 shares of the company’s stock worth $341,000 after purchasing an additional 1,393 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Syneos Health by 10.7% in the 3rd quarter. Louisiana State Employees Retirement System now owns 16,600 shares of the company’s stock worth $856,000 after purchasing an additional 1,600 shares in the last quarter. Advisors Asset Management Inc. boosted its position in shares of Syneos Health by 12.0% in the 2nd quarter. Advisors Asset Management Inc. now owns 17,216 shares of the company’s stock worth $362,000 after purchasing an additional 1,841 shares in the last quarter. Pendal Group Ltd boosted its position in shares of Syneos Health by 4.8% in the 2nd quarter. Pendal Group Ltd now owns 40,577 shares of the company’s stock worth $1,903,000 after purchasing an additional 1,848 shares in the last quarter. Finally, First Manhattan Co. bought a new stake in shares of Syneos Health in the 3rd quarter worth approximately $103,000.
Several equities analysts recently issued reports on the company. Barclays reaffirmed a “hold” rating and issued a $51.00 price objective (up from $43.00) on shares of Syneos Health in a research report on Friday, August 3rd. UBS Group assumed coverage on Syneos Health in a research report on Tuesday, October 9th. They issued a “buy” rating and a $60.00 price objective on the stock. Mizuho reaffirmed a “hold” rating and issued a $51.00 price objective on shares of Syneos Health in a research report on Monday, August 6th. Evercore ISI assumed coverage on Syneos Health in a research report on Thursday, October 4th. They issued an “outperform” rating and a $58.00 price objective on the stock. Finally, ValuEngine raised Syneos Health from a “sell” rating to a “hold” rating in a research report on Saturday, September 22nd. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Syneos Health presently has an average rating of “Buy” and a consensus price target of $53.91.
SYNH stock opened at $46.55 on Friday. The company has a market capitalization of $4.56 billion, a P/E ratio of 20.25, a price-to-earnings-growth ratio of 1.05 and a beta of 0.81. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 1.01. Syneos Health Inc has a 12-month low of $31.10 and a 12-month high of $59.45.
Syneos Health (NASDAQ:SYNH) last announced its earnings results on Thursday, August 2nd. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.09 billion. Syneos Health had a negative net margin of 4.32% and a positive return on equity of 7.80%. The firm’s quarterly revenue was up 315.5% on a year-over-year basis. As a group, analysts forecast that Syneos Health Inc will post 2.42 EPS for the current year.
In other Syneos Health news, major shareholder H. Lee Equity Fund Vi Thomas sold 6,000,000 shares of the business’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $49.73, for a total transaction of $298,380,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.57% of the stock is currently owned by insiders.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Recommended Story: What is a Fiduciary?
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.